Cathay Biotech Inc. (SHA:688065)

Market Cap	31.36B -8.7%
Revenue (ttm)	3.39B +11.3%
Net Income	589.49M +13.2%
EPS	0.82 -7.4%
Shares Out	720.66M
PE Ratio	52.78
Forward PE	35.88
Dividend	0.45 (1.00%)
Ex-Dividend Date	Aug 1, 2025

Volume	5,001,039
Open	44.60
Previous Close	44.88
Day's Range	43.40 - 44.75
52-Week Range	39.51 - 64.50
Beta	0.47
Analysts	Strong Buy
Price Target	68.44 (+57.3%)
Earnings Date	Aug 14, 2026

About Cathay Biotech

Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for electrification, automation, and digitization for biological manufacturing. The company’s products are used in textiles, pharmaceuticals, perfumes, aut...

• Industry: Chemicals
• Sector: Materials
• Founded: 2000
• Employees: 1,761
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688065

Financial Performance

In 2025, Cathay Biotech's revenue was 3.30 billion, an increase of 11.40% compared to the previous year's 2.96 billion. Earnings were 560.72 million, an increase of 14.68%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 16, 2026

Data Sources Report a data error